



(11)

EP 2 905 338 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
C12N 15/85 ^(2006.01) **A01K 67/027** ^(2006.01)
C07K 16/00 ^(2006.01) **C07K 16/46** ^(2006.01)
C07K 16/18 ^(2006.01)

(48) Corrigendum issued on:
24.01.2018 Bulletin 2018/04

(45) Date of publication and mention
of the grant of the patent:
02.08.2017 Bulletin 2017/31

(21) Application number: **14198318.9**

(22) Date of filing: **22.06.2011**

(54) **Transgenic mice with a modified endogenous lambda immunoglobulin locus**

Transgene Mäuse mit einer modifizierten endogenen lambda Immunglobulin-Locus

Souris transgéniques avec un locus endogène d'immunoglobulin lambda modifié

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **22.06.2010 US 357314 P**
22.06.2010 US 357317 P

(43) Date of publication of application:
12.08.2015 Bulletin 2015/33

(60) Divisional application:
17162880.3 / 3 205 726

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
11728508.0 / 2 480 675

(73) Proprietor: **Regeneron Pharmaceuticals, Inc.**
Tarrytown, NY 10591 (US)

(72) Inventors:
• **Murphy, Andrew J.**
Croton-on-Hudson, NY 10520 (US)

- **Stevens, Sean**
San Diego, CA 92122 (US)
- **Gurer, Cagan**
Valhalla, NY 10595 (US)
- **Macdonald, Lynn**
White Plains, NY 10605 (US)
- **Hosiawa, Karolina A.**
Tarrytown, NY 10591 (US)

(74) Representative: **J A Kemp**
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:
WO-A1-00/26373 **WO-A1-2011/004192**
WO-A2-2008/054606 **WO-A2-2009/143472**
WO-A2-2010/039900 **US-A1- 2002 026 036**
US-A1- 2003 217 373 **US-A1- 2006 015 957**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 905 338 B8

- | | |
|---|---|
| <ul style="list-style-type: none">• POPOV A V ET AL: "A HUMAN IMMUNOGLOBULIN L LOCUS IS SIMILARLY WELL EXPRESSED IN MICE AND HUMANS", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 189, no. 10, 17 May 1999 (1999-05-17) , pages 1611-1619, XP000891331, ISSN: 0022-1007, DOI: 10.1084/JEM.189.10.1611 | <ul style="list-style-type: none">• GORMAN J R ET AL: "THE LGK 3' ENHANCER INFLUENCES THE RATIO OF LGK VERSUS LGL B LYMPHOCYTES", IMMUNITY, CELL PRESS, US, vol. 5, no. 3, September 1996 (1996-09), pages 241-252, XP000891305, ISSN: 1074-7613, DOI: 10.1016/S1074-7613(00)80319-2 |
|---|---|